share_log

HC Wainwright & Co. Reiterates Buy on Halozyme Therapeutics, Maintains $65 Price Target

Benzinga ·  Sep 13 18:36  · Ratings

HC Wainwright & Co. analyst Mitchell Kapoor reiterates Halozyme Therapeutics (NASDAQ:HALO) with a Buy and maintains $65 price target.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment